Icagen, which recently terminated trials of its lead drug candidate that would have treated sickle cell anemia, is expanding its drug discovery and development panel.
Joining the panel, which had included two people, are:
• William Catterall, professor and chairman, Department of Pharmacology at the University of Washington since 1984.
• Christine Sang, director of the Translational Pain Research Program at Brigham and Women’s Hospital and Harvard Medical School.
• Cheryl Zimmerman, professor and director of Graduate Studies, Department of Pharmaceutics at the University of Minnesota.
